83 FR 12582 - 2018 Center for Biologics Evaluation and Research Science Symposium

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 83, Issue 56 (March 22, 2018)

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public symposium entitled ``2018 Center for Biologics Evaluation and Research Science Symposium.'' The purpose of the public symposium is to discuss scientific topics related to the regulation of biologics and highlight science conducted at the Center for Biologics Evaluation and Research (CBER) by showcasing how scientific research informs regulatory decision making and to provide a forum for developing collaborations within FDA and with external organizations. The symposium will include presentations by experts from academic institutions, government agencies, and research institutions.

[Federal Register Volume 83, Number 56 (Thursday, March 22, 2018)]
[Notices]
[Page 12582]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-05805]



[[Page 12582]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-N-1094]


2018 Center for Biologics Evaluation and Research Science 
Symposium

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public symposium.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is 
announcing the following public symposium entitled ``2018 Center for 
Biologics Evaluation and Research Science Symposium.'' The purpose of 
the public symposium is to discuss scientific topics related to the 
regulation of biologics and highlight science conducted at the Center 
for Biologics Evaluation and Research (CBER) by showcasing how 
scientific research informs regulatory decision making and to provide a 
forum for developing collaborations within FDA and with external 
organizations. The symposium will include presentations by experts from 
academic institutions, government agencies, and research institutions.

DATES: The public symposium will be held on June 25 and 26, 2018, from 
9 a.m. to 3 p.m. See the SUPPLEMENTARY INFORMATION section for 
registration date and information.

ADDRESSES: The public symposium will be held at FDA's White Oak campus, 
10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room 
(Rm. 1503), Silver Spring, MD 20993. Entrance for the public symposium 
participants (non-FDA employees) is through Bldg. 1, where routine 
security check procedures will be performed. For parking and security 
information, please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.

FOR FURTHER INFORMATION CONTACT: Sherri Revell or Loni Warren 
Henderson, Food and Drug Administration, Center for Biologics 
Evaluation and Research, 10903 New Hampshire Ave., Bldg. 71, Rm. 1118, 
Silver Spring, MD 20993, 240-402-8010, email: 
[email protected] (subject line: CBER Science Symposium).

SUPPLEMENTARY INFORMATION: 

I. Background

    The purpose of the public symposium is to discuss scientific topics 
related to the regulation of biologics and highlight science conducted 
at CBER by showcasing how scientific research informs regulatory 
decision making and to provide a forum for developing collaborations 
within FDA and with external organizations.

II. Topics for Discussion at the Public Symposium

    The public symposium will include presentations on the following 
topics: (1) Emerging and re-emerging diseases; (2) diverse types of 
data in regulatory decision making; (3) immune response to vaccination; 
(4) immunotherapy; (5) new technologies for research and treatments; 
(6) the role of the microbiome in human disease; and (7) regenerative 
medicine.

III. Participating in the Public Symposium

    Registration: To register for the public symposium, please visit 
the following website: https://www.eventbrite.com/e/2018-center-for-biologics-evaluation-and-research-cber-science-symposium-tickets-39525851887. Please provide complete contact information for each 
attendee, including name, title, affiliation, address, email, and 
telephone.
    Registration is free and based on space availability, with priority 
given to early registrants. Persons interested in attending this public 
symposium (either in person or by webcast) (see Streaming Webcast of 
the Public Symposium) must register online by June 18, 2018, midnight 
Eastern Time. Early registration is recommended because seating is 
limited. There will be no onsite registration; therefore, FDA may limit 
the number of participants from each organization. Registrants will 
receive confirmation when they have been accepted.
    If you need special accommodations, due to a disability, please 
contact Sherri Revell or Loni Warren Henderson no later than June 11, 
2018.
    Streaming Webcast of the Public Symposium: This public symposium 
will also be webcast. A link to the live webcast of this symposium will 
be provided upon registration at https://www.eventbrite.com/e/2018-center-for-biologics-evaluation-and-research-cber-science-symposium-tickets-39525851887. Persons interested in viewing the live webcast 
must register online by June 18, 2018. Early registration is 
recommended because webcast connections are limited. A video record of 
the public symposium will be available at https://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/default.htm for 1 year.
    If you have never attended a Connect Pro event before, test your 
connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program, 
visit https://www.adobe.com/go/connectpro_overview. FDA has verified 
the website addresses in this document as of the date this document 
publishes in the Federal Register, but websites are subject to change 
over time.

    Dated: March 1, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-05805 Filed 3-21-18; 8:45 am]
 BILLING CODE 4164-01-P